About Us

Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics peptides).

Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.

Enterome’s Mimicry drug discovery platform uses best-in-class biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20+ million full-length gut microbiome proteins. This platform is highly productive and has already generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.

Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones or cytokines. The Company is presently advancing its proprietary OncoMimics pipeline of distinct drug candidates – EO2401 in glioblastoma and adrenal tumors, EO2463 in indolent non-Hodgkin lymphomas, and EO4010 for third-line colorectal cancer.

Key Figures

Key Figure

20+ million

full length and functional proteins from the gut microbiome

Key Figure

116 million

financing raised

Key Figure

21 patent families filed

3 in-licensed patent families,
9 Trademarks filed

Key Figure

70

employees

Our leadership team

Team Member
Pierre Belichard, Ph.D., M.B.A
Chief Executive Officer –
Co founder
Team Member
Marie-Laure Bouttier
Chief Corporate Officer –
Co founder
Team Member
Christelle Dumoussaud
Chief Financial Officer
Team Member
Jan Fagerberg, M.D., Ph.D.
Chief Medical Officer
Team Member
Laurent Chene, Ph.D.
Head of the Drug Discovery platform
Team Member
Lucie Rouch
Chief Clinical Operations Officer
Team Member
Joël Richard, Ph.D., HDR
Chief Development Officer
Team Member
William Hariri, MSc
Chief Business Officer

Board of Directors

Team Member
Georges Gemayel, Ph.D.
Chairman of the Board
Team Member
Pierre Belichard, Ph.D., M.B.A.
Chief Executive Officer –
Co founder
Team Member
Pierre Cassigneul, M.B.A.
Director / Independent
Team Member
Isabelle de Cremoux
Director / Seventure Partners
Team Member
Hans-Juergen Woerle, M.D.
Director / Nestlé
Team Member
Lars Gredsted
Director / Lundbeckfonden BioCapital
Team Member
Luca Marini, M.B.A.
Director / Xyence Capital SGR
Team Member
Mary Thistle
Director / Independent
Team Member
Peter Hirth, Ph.D.
Director / Independent

Scientific Advisory Board

David Klatzmann
MD, PhD
Professor of Immunology at the Sorbonne University (Paris, France)
Pedro Romero
MD, PhD
Director of Scientific and Medical Affairs, Novigenix, Professor Emeritus at University of Lausanne (Lausanne, Switzerland)
Justin Eyquem
PhD
Assistant Professor in Microbiology and Immunology at the University of California (San Francisco, CA, US)

Medical Advisory Group

Zuzana Jirakova
MD, PhD
Chief Medical Officer at Highlight Therapeutics (Madrid, ES)
Peter Kiener
PhD
Venture Partner at ICG Life Sciences (Naples, FL, US)
Alexander Zukiwski
MD
Chief Medical Officer at CASI Pharmaceuticals (Rockville, MD, US)

Partners

Enterome signed a clinical trial collaboration and supply agreement with Bristol Myers Squibb in March 2021 to support EO2401, an OncoMimicsTM vaccine in clinical development.

As a result of this agreement, BMS has committed to the supply, free of charge, of nivolumab for patients participating in the combined therapy clinical trials ROSALIE (EOGBM1-18) and SPENCER (EOADR1-19).

In July 2022 Enterome signed a major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease.

Under the terms of the agreement, Enterome has received a €40 million upfront payment from Nestlé Health Science, in cash and in equity, and is also eligible to receive clinical and sales milestones payments for each licensed therapeutic candidate, plus royalties on net sales. Enterome will be responsible for leading drug discovery activities and bear related costs up to investigational new drug (IND) application.

Investors

Enterome was established in 2012 and has raised €135 million in financing rounds with private equity funds, strategic investors and in loans.

Enterome France

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex